Literature DB >> 12406020

Captopril and quinapril reduce reactive oxygen species.

M van der Giet1, M Erinola, W Zidek, M Tepel.   

Abstract

BACKGROUND: Angiotensin-converting enzyme inhibitors may affect reactive oxygen species in humans in vitro and in vivo. In the present study we evaluated whether angiotensin-converting enzyme inhibitors may affect NAD(P)H oxidase activity.
MATERIALS AND METHODS: The production of reactive oxygen species was measured spectrophotometrically in mononuclear leukocytes using the fluorescent dye, dichlorofluorescein diacetate. The effects of quinaprilat, captopril, enalaprilat and lisinopril on phorbol myristate acetate-induced reactive oxygen species generation were investigated in vitro. The effects of quinaprilat, captopril, enalaprilat and lisinopril on the NAD(P)H oxidase activity of the mononuclear leukocytes were measured photometrically. In addition, reactive oxygen species were measured before and 4 h after oral administration of quinapril.
RESULTS: In vitro, the addition of quinaprilat (72 +/- 6% of control; mean +/- SEM; n= 19; P < 0.001) and captopril (48 +/- 2% of control; n= 19; P < 0.001) significantly reduced the phorbol-12-myristate-13-acetate-induced reactive oxygen species generation by the mononuclear leukocytes, whereas enalaprilat and lisinopril showed no effect. The effect of captopril on phorbol-12-myristate-13-acetate-induced reactive oxygen species generation in vitro was concentration-dependent. Quinaprilat and captopril significantly inhibited the NAD(P)H oxidase activity. After the oral administration of 10 mg of quinapril the phorbol-12-myristate-13-acetate-induced reactive oxygen species generation by the mononuclear leukocytes was significantly decreased from 1981 +/- 292% to 988 +/- 141% (n = 14; P < 0.01).
CONCLUSION: Quinapril and captopril decrease the production of reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406020     DOI: 10.1046/j.1365-2362.2002.01064.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Captopril improves cerebrovascular structure and function in old hypertensive rats.

Authors:  François Dupuis; Jeffrey Atkinson; Patrick Limiñana; Jean-Marc Chillon
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

2.  Blood pressure normalization via pharmacotherapy improves cutaneous microvascular function through NO-dependent and NO-independent mechanisms.

Authors:  Daniel H Craighead; Caroline J Smith; Lacy M Alexander
Journal:  Microcirculation       Date:  2017-10       Impact factor: 2.628

3.  Bradykinin-induced dilation of human coronary arterioles requires NADPH oxidase-derived reactive oxygen species.

Authors:  Brandon T Larsen; Aaron H Bubolz; Suelhem A Mendoza; Kirkwood A Pritchard; David D Gutterman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-02-12       Impact factor: 8.311

Review 4.  Oxidative stress and vascular function: implications for pharmacologic treatments.

Authors:  Antje R Weseler; Aalt Bast
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

5.  Endothelial Vascular Function in Hypertensive Patients After Renin-Angiotensin System Blockad.

Authors:  Leon Adriana Souza-Barbosa; S Lvia E Ferreira-Melo; Samira Ubaid-Girioli; Eduardo Arantes Nogueira; Juan Carlos Yugar-Toledo; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-11       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.